R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).
Issa F. Khouri,Rima M. Saliba,Chitra Hosing,Rosamar Valverde,William D. Erwin,Luis Fayad,Farzaneh Maadani,Martin Korbling,Grace-Julia Okoroji,Anne Stachowiak,Barry I. Samuels,Paolo Anderlini,Daniel R. Couriel,Marcos de Lima,Sergio Giralt,Uday R. Popat,Partow Kebriaei,Naoto T. Ueno,Muzaffar H. Qazilbash,Peter McLaughlin,Fredrick B. Hagemeister,Anas Younes,Donald A. Podoloff,Richard E. Champlin +23 more
TL;DR: The combination of 90Y ibritumomab tiuxetan at 0.4mCI/kg with BEAM is safe and effective in NHL patients undergoing autologous SCT, and further studies are needed to explore its role in NST.
Journal ArticleDOI
Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers.
TL;DR: It is concluded that managing TIGF involves risk assessment, provision of information, discussion of potential options for preserving fertility, and referral to appropriate specialists.
Journal ArticleDOI
NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation
TL;DR: The current status of clinical investigation using NK cell therapy for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation is discussed.
Journal ArticleDOI
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs
Lohith Gowda,Mithun Vinod Shah,Ifra Badar,Qaiser Bashir,Nina Shah,Krina K. Patel,Rashmi Kanagal-Shamanna,Rohtesh S. Mehta,Donna M. Weber,Hans C. Lee,Elisabet E. Manasanch,Abdul Rashid Shah,Sheeba K. Thomas,Simrit Parmar,Yago Nieto,Robert Z. Orlowski,Richard E. Champlin,Muzaffar H. Qazilbash +17 more
TL;DR: Outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents are reported.
Journal ArticleDOI
Myeloablative therapy for primary resistant multiple myeloma.
TL;DR: Current myeloablative regimens supported by autologous stem cells provided a useful treatment for patients who had advanced primary resistant multiple myeloma and should be given early in the disease course to provide the best chance for remission.